Etoposide sensitivity of radioresistant human glioma cell lines

被引：2

作者：

Beauchesne P. ^{[1
,4
]}

Bertrand S. ^{[2
]}

N'Guyen M.J. ^{[2
]}

Christianson T. ^{[1
]}

Dore J.F. ^{[2
]}

Mornex F. ^{[3
]}

Bonner J.A. ^{[1
]}

机构：

[1] Department of Radiation Oncology, Mayo Clinic Center, Rochester, MN

[2] INSERM U453, Centre Léon Bérard, Lyon

[3] Service de Radiothérapie, Centre Léon Bérard, Lyon

[4] Neurochirurgie, Ctr. Hosp. Univ. de Saint - Etienne, Hôpital Bellevue

来源：

Cancer Chemotherapy and Pharmacology | 1997年 / 41卷 / 2期

关键词：

Etoposide; Human malignant gliomas; Radioresistance; Topoisomerase II;

D O I：

10.1007/s002800050713

中图分类号：

学科分类号：

摘要：

Purpose: Malignant gliomas display aggressive local behavior and are not cured by existing therapy. Etoposide, a topoisomerase-II-inhibitor agent, is one of the most active and useful antineoplastic agents. However, etoposide is not usually used on these tumors. We undertook an in vitro study to prove that etoposide is a useful drug for malignant gliomas. Methods: Five human glioma cell lines were the basis for this study. Following exposure to various concentrations of etoposide, the glioma cell lines were found to be sensitive; the median concentration inhibiting the number of cells by 50% (IC50) was 8.76 μg/ml (range 8-15.8 μg/ml). Since topoisomerase II is the critical target for etoposide, it was of interest to determine the topoisomerase II activity (decatenation of kinetoplast DNA isolated from Cryphtidia fasciculata) and the etoposide-induced inhibition of topoisomerase II activity. Results: The topoisomerase II activity was homogeneous in glioma cell lines (average of 50% decatenation with 7,000 cells), and topoisomerase II was the target of the etoposide. Conclusions: Our results suggest that topoisomerase II-reactive agents may prove to be clinically useful drugs for patients with malignant gliomas.

引用

页码：93 / 97

页数：4

共 37 条

[31]

Mousseau M., Cahuvin C., Nissou M.F., Chaffanet M., Plantaz D., Pasquier B., Schaerer R., Benabid A., A study of the expression of 4 chemoresistance-related genes in human primary and metastatic brain tumours, Eur J Cancer, 5, pp. 753-759, (1993)

[32]

Nakagawa H., Fujita T., Kubo S., Tsuruzono K., Yamada M., Tokiyoshi K., Miyawaki Y., Kanayama T., Kadota T., Hayakawa T., Selective intra-arterial chemotherapy with a combination of etoposide and cisplatin for malignant gliomas: Preliminary report, Surg Neurol, 41, pp. 19-27, (1994)

[33]

Pommier Y., Kerrigan D., Schwartz R., The formation and resealing of intracalator-induced DNA strand breaks in isolated L1210 cell nuclei, Biochem Biophys Res Commun, 107, pp. 576-583, (1982)

[34]

Seabright M., A rapid banding technique for human chromosomes, Lancet, 2, pp. 971-972, (1971)

[35]

Slevin M.L., The clinical pharmacology of etoposide, Cancer, 67, pp. 319-329, (1991)

[36]

Tirelli U., D'Incalci M., Canetta R., Tumulo S., Franchin G., Veronesi A., Galligioni E., Trovo M.G., Rossi C., Grigoletto E., Etoposide (vp 16-213) in malignant brain tumours: A phase II study, J Clin Oncol, 2, pp. 432-436, (1984)

[37]

Walker M.D., Strike T.A., Sheline G.E., An analysis of dose-effect relationship in the radiotherapy of malignant gliomas, Int J Radiat Oncol Biol Phys, 5, pp. 1725-1731, (1979)

← 1 2 3 4 →